Genetic polymorphism biotransformation of azathioprine and treatment of inflammatory bowel diseases;Polymorphisme génétique et traitement des maladies inflammatoires chroniques de l'intestin: Exemple de l'azathioprine

Therapie

Volumn 59, Issue 1, 2004, Pages 71-75

  Bessard, Germain ^a   Hardy, Gaëlle ^a   Chartier, Alain ^a   Stanke Labesque, Françoise ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

Azathioprine; Inflammatory bowel disease; Mercaptopurine; Single nucleotide polymorphism; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; DNA; MERCAPTOPURINE; RNA; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

APLASIA; BIOTRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DETOXIFICATION; DNA SYNTHESIS; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERANCE; DRUG TRANSFORMATION; ENTERITIS; ENZYME MECHANISM; ENZYME SYNTHESIS; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LEUKOPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RNA SYNTHESIS;

EID: 2942674320     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004015     Document Type: Conference Paper

References (20)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39
2. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9
3. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64
4. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001; 1: 254-61
5. Otterness DM, Szumlanski CL, Lennard L, et al. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1997; 62: 60-73
6. Cuffari C, Théorêt Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6
7. Dubinski MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13
8. Cuffari C, Hunt S, Bayless T. Utilisation of 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6
9. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64
10. Erdmann GR, France LA, Bostrom BC, et al. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methyl-mercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990; 4: 47-51
11. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methyl-mercaptopurine metabolites in a single sample. J Chromatogr 1992; 583: 83-90
12. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cell by HPLC. Clin Chem 1998; 44: 551-5
13. Shipkova M, Amstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003; 49: 260-8
14. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54
15. Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol 2001; 35: 756-64
16. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyl-transferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2
17. Jacqz-Aigrain E, Bessa E, Medard Y, et al. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994; 38: 1-8
18. Anglicheau D, Sanquer S, Loriot MA, et al. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr 2002; 773: 119-27
19. de Jong D, Mulder CJ, van Sorge AA. Why measure thiopurine methyltransferase activity?: direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine [letter]. Gut 2001; 49: 874
20. Derijks LJJ, de Jong DJ, Gilissen LPL, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-7